KCFA
ADAP
Key Client Fiduciary Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $42.1K | Buy |
175,555
+25,405
| +17% | +$6.09K | 0.02% | 203 |
|
|
2025
Q1 | $29.6K | Sell |
150,150
-105,209
| -41% | -$20.7K | 0.01% | 187 |
|
|
2024
Q4 | $138K | Hold |
255,359
| – | – | 0.06% | 185 |
|
|
2024
Q3 | $243K | Sell |
255,359
-8,630
| -3% | -$8.2K | 0.11% | 171 |
|
|
2024
Q2 | $257K | Sell |
263,989
-4,666
| -2% | -$4.55K | 0.13% | 151 |
|
|
2024
Q1 | $424K | Sell |
268,655
-67,965
| -20% | -$107K | 0.23% | 111 |
|
|
2023
Q4 | $267K | Buy |
336,620
+20,295
| +6% | +$16.1K | 0.15% | 140 |
|
|
2023
Q3 | $247K | Sell |
316,325
-12,830
| -4% | -$10K | 0.15% | 142 |
|
|
2023
Q2 | $304K | Buy |
329,155
+8,000
| +2% | +$7.4K | 0.18% | 126 |
|
|
2023
Q1 | $350K | Buy |
321,155
+24,415
| +8% | +$26.6K | 0.22% | 105 |
|
|
2022
Q4 | $433K | Sell |
296,740
-139,245
| -32% | -$203K | 0.29% | 79 |
|
|
2022
Q3 | $469K | Buy |
435,985
+19,819
| +5% | +$21.3K | 0.42% | 46 |
|
|
2022
Q2 | $707K | Sell |
416,166
-4,281
| -1% | -$7.27K | 0.69% | 34 |
|
|
2022
Q1 | $866K | Buy |
420,447
+164,399
| +64% | +$339K | 0.68% | 37 |
|
|
2021
Q4 | $960K | Buy |
+256,048
| New | +$960K | 0.79% | 34 |
|